Resistance mechanisms associated with altered intracellular distribution of anticancer agents.
about
LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signalingLysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cellsChemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin CifWhere is it and How Does it Get There - Intracellular Localization and Traffic of P-glycoproteinCancer nanotechnology: emerging role of gold nanoconjugatesOvercoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeuticsAn integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase IIPhotoacoustic "nanobombs" fight against undesirable vesicular compartmentalization of anticancer drugsImidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers.Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.Trafficking microenvironmental pHs of polycationic gene vectors in drug-sensitive and multidrug-resistant MCF7 breast cancer cells.Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cellsBio-metals imaging and speciation in cells using proton and synchrotron radiation X-ray microspectroscopyMesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.Photochemical internalization-mediated delivery of chemotherapeutic agents in human breast tumor cell lines.Evaluation of the pharmacophoric motif of the caged Garcinia xanthonesActivating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression.Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids.Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiationPterostilbene-induced tumor cytotoxicity: a lysosomal membrane permeabilization-dependent mechanismInfluence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages.Sequestration of AS-DACA into acidic compartments of the membrane trafficking system as a mechanism of drug resistance in rhabdomyosarcomaChemistry and biology of the caged Garcinia xanthones.Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin's LymphomaSelective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent.The relationship between LAPTM4B polymorphisms and cancer risk in Chinese Han population: a meta-analysis.Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cellsIntracellular trafficking of P-glycoprotein.An overview of the evidence and mechanisms of herb-drug interactions.Chemosensitization of doxorubicin in multidrug-resistant cells by unimolecular micelles via increased cellular accumulation and apoptosis.Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance.Effects of pH-sensitive chain length on release of doxorubicin from mPEG-b-PH-b-PLLA nanoparticles.Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cellsTumor acidity, chemoresistance and proton pump inhibitors.Nanotechnology for targeted cancer therapy.Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells.Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor.
P2860
Q24296238-71C8EA37-56C7-45BB-BA61-0D3CC5575F69Q24606012-B7B0053E-DA7C-47FA-917C-BA257A0478BEQ24647608-F97B3AEC-3C2C-41B9-A7D2-4EA34EEDCF96Q27008624-47296C86-7976-4DFA-B385-AF85B45A138AQ27021820-7C9F5CEE-444B-43FD-983B-1961829AA17AQ27304425-AB6EF583-570D-4AE4-9D7D-C12071F2DEA1Q28476505-4215E1AC-2705-4B99-B78F-001E69E1FBF2Q30399655-66B13760-4A29-4058-965F-5860FA2FB3E0Q30514153-0B04702F-B7BF-4D73-886F-41AFF52BDE09Q31129007-33C6EE0A-C747-4D9F-97E0-832CC961DFA4Q33184060-4E5BFE19-2B05-4BCD-A4A2-AA960F8C4290Q33684568-D4F376FF-032D-44A1-9AEC-E17F7B5408E2Q33708231-F305A350-897E-4920-8054-0D4B8FBB5C12Q33747196-5F3DA750-D860-45F1-9ADE-D0B1EFA589BFQ34011106-346C303C-67C1-49BD-87FB-20E4CA2E1E8FQ34014475-E8B12144-A34B-4BB0-808D-A3E4CFDE636CQ34082596-6D1E2277-0762-4A5F-95D6-77A2C1B7BC11Q34170941-6476ABBC-9176-4D1C-BCE3-61B9FA4B0ED3Q34384873-CCF42F8A-8940-40A8-A3B8-A2F178357275Q34405013-24ACC97A-A31F-4F6A-8477-9987ECFC36F9Q34408186-EE3EE640-ECB9-4562-8B5B-045DE8B66068Q34734399-E24247BB-DFB0-4F56-8E75-49E5EEF50B00Q34782810-51AC78E9-AC3E-4FE5-96A2-970169F43DBCQ35129332-30E099C5-FBE9-4E7D-8285-EFD54BEFF0B0Q35158345-1D0DA985-3956-4CE7-9722-02F528703857Q35163699-9D3EB89A-EC6C-4959-8374-690A651D2E91Q35533654-8A62D6AD-E547-4A74-92BB-9E690820504BQ35657923-8673787F-2B99-4254-8306-EEAAB68E69DCQ35784974-7A0BC6F6-CF50-4E19-B781-98DC5ED827E4Q35919968-D15D9957-B287-4BFF-AF66-7576C2B92116Q35928030-EEB43BC1-FFA7-404A-A7BA-271E78899355Q36088702-FF397BAB-8178-4A69-9888-E031E14C6030Q36176104-4785B2D7-EEAD-41C7-9D6A-BA5F0A7798D9Q36210924-FCE98B68-C59F-42D6-9E5A-3440336FDBFFQ36262935-6186C58A-606D-46D2-926C-967FD5A2494AQ36346111-D0B655AE-0BC3-473A-9F6A-AC1714D50400Q36429624-5EBED234-C423-4F1A-9858-8D8E5F20E10EQ36842770-EFC92216-F711-431A-845D-DCEBF9CF8358Q36913097-A8F5066E-41E3-4B75-B71C-B41F586C0434Q36920351-C81A88A3-C5E3-465F-942B-B158937118DF
P2860
Resistance mechanisms associated with altered intracellular distribution of anticancer agents.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Resistance mechanisms associat ...... ribution of anticancer agents.
@ast
Resistance mechanisms associat ...... ribution of anticancer agents.
@en
type
label
Resistance mechanisms associat ...... ribution of anticancer agents.
@ast
Resistance mechanisms associat ...... ribution of anticancer agents.
@en
prefLabel
Resistance mechanisms associat ...... ribution of anticancer agents.
@ast
Resistance mechanisms associat ...... ribution of anticancer agents.
@en
P1476
Resistance mechanisms associat ...... tribution of anticancer agents
@en
P2093
A K Larsen
A Skladanowski
P304
P356
10.1016/S0163-7258(99)00073-X
P577
2000-03-01T00:00:00Z